251P - Association of Epstein-Barr virus with prognosis of patients with esophageal squamous cell carcinoma: A retrospective cohort study

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Oesophageal Cancer
Cancer in Special Situations
Presenter Soodabeh Shahidsales
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors S. Shahidsales1, A. Moradi2, F. Ghasemi3, K. Anvari1, S. Ahmadi-Simab4, M.T. Boroushaki5, A. Avan3
  • 1Radiation Oncology, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 9176613775 - Mashhad/IR
  • 2Department Of Biology, Islamic Azad University, 000000000 - damghan/IR
  • 3Department Of Modern Sciences And Technologies, Mashhad University of Medical Sciences, 000000000 - Mashhad/IR
  • 4Cancer Research Center, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 000000000 - Mashhad/IR
  • 5Department Of Pharmacology And Pharmacological, Mashhad University of Medical Sciences, 000000000 - Mashhad/IR



Esophageal squamous cell carcinoma (ESCC) is among the leading cause of cancer related death within gastrointestinal tumors. There is growing body of evidence showing the association of Epstein Barr Virus (EBV) infection with the development of malignancies including B-cell non-Hodgkin lymphoma, Hodgkin disease and Burkett lymphoma, although its potential association with ESCC is still controversial. Therefore in the present study we explored the association of EBV with pathological information and clinical outcome of 108 ESCC patients.


This retrospective cohort study included 141 cases of ESCC identified at Omid hospital of Mashhad University of Medical Science between July 2005 to September 2014. The ESCC tissue was stained with H&E, follow by DNA extraction. The present of EBV was evaluated using an Epstein-Barr virus PCR detection Kit. Univariate/multivariate analyses were employed to investigate the association of EBV with overall survival and progression free survival.


Among the patients, 48% of patients were female, and 52% were male with mean age of 59.2±11.1yr. 5.6%, 21.3%, and 71.3% of patients were T1, T2, T3, respectively, while 32.4% of patients had lymph node metastases. In order to explore whether patient characteristics might influence clinical outcome, we analyzed data on PFS and OS according to patients’ clinicopathological features. Tumor size, node and metastasis status, and stage were associated with shorter OS and PFS. Of note we observed the present of EBV in 6.5% patients, and 100% of EBV infected patients were at T2 and T3, while 42.8% of these patients had lymph node positive. EBV positive patients were associated with more advanced stages


our findings demonstrate the presence of EBV in 6.5% of Iranian patients and its potential link with tumor size, supporting further studies in multi-center setting to determine its association with development and progression of ESCC

Clinical trial indentification

Legal entity responsible for the study



Mashhad University of Medical Sciences


All authors have declared no conflicts of interest.